$205.70
-8.30-3.88%
Last update: Oct 26, 4:49 PM
Jazz Pharmaceuticals PLC (JAZZ) Stock Price, Quote, News & History
JAZZNASDAQ
FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.
You can purchase shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) through any online brokerage.
Other companies in Jazz Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Jazz Pharmaceuticals has a consensus price target of $264.52.
The stock price for Jazz Pharmaceuticals (NASDAQ: JAZZ) is $205 last updated October 26, 2026 at 4:49 PM EDT.
There are no upcoming dividends for Jazz Pharmaceuticals.
Jazz Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Jazz Pharmaceuticals.
Jazz Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav...
